Currently we have one US Clinical trial that is enrolling patients with NYHA Classification II and III.

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210)

NCT01251406

This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of Neucardin™ as a treatment for stable chronic heart failure.

A total of 120 subjects, who have chronic heart failure with a NYHA classification of II or III, and are on a stable regimen of ACEI/angiotensin receptor blocker (ARB), beta-blocker, and/or diuretic for at least 3 months prior to receiving study medication and anticipated to remain on the stable regimen through the treatment period can enroll as per specific inclusion and exclusion criteria.

Subjects will be hospitalized for 10 days during the treatment period and will be infused subcutaneously with rhNRG-1 or placebo.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01251406